Cliff Asness’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$676K Buy
19,683
+3,991
+25% +$120K ﹤0.01% 3233
2026
Q1
$374K Buy
15,692
+2,488
+19% +$69K ﹤0.01% 3292
2025
Q4
$366K Buy
13,204
+1,978
+18% +$50.5K ﹤0.01% 3078
2025
Q3
$272K Sell
11,226
-14,195
-56% -$282K ﹤0.01% 3128
2025
Q2
$432K Buy
+25,421
New +$443K ﹤0.01% 2696
2024
Q4
Sell
-8,842
Closed -$217K 2876
2024
Q3
$217K Sell
8,842
-169
-2% -$4.37K ﹤0.01% 2528
2024
Q2
$211K Buy
9,011
+2,487
+38% +$61.1K ﹤0.01% 2406
2024
Q1
$216K Buy
+6,524
New +$203K ﹤0.01% 2237
2023
Q1
Sell
-9,599
Closed -$375K 2166
2022
Q4
$375K Sell
9,599
-42
-0.4% -$1.88K ﹤0.01% 1913
2022
Q3
$459K Buy
+9,641
New +$550K ﹤0.01% 1820
2022
Q1
Sell
-7,424
Closed -$592K 2218
2021
Q4
$592K Sell
7,424
-15,304
-67% -$1.31M ﹤0.01% 1777
2021
Q3
$1.98M Buy
22,728
+4,228
+23% +$425K ﹤0.01% 1155
2021
Q2
$2.38M Buy
18,500
+7,979
+76% +$636K ﹤0.01% 1131
2021
Q1
$842K Buy
10,521
+2,122
+25% +$202K ﹤0.01% 1626
2020
Q4
$686K Buy
+8,399
New +$413K ﹤0.01% 1664

Other funds holding BEAM

Cliff Asness's BEAM Position: Q2 2026 in Review

Cliff Asness increased its Beam Therapeutics (BEAM) stake by 25% in Q2 2026, buying an estimated $120K and bringing the position to 19,683 shares worth $676K. The position accounts for ﹤0.01% of the portfolio, ranked #3233.

Cliff Asness first reported a position in BEAM in Q4 2020 and has held it in 15 quarters since. The position peaked at $2.38M in Q2 2021. 275 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Cliff Asness held 19,683 shares of Beam Therapeutics worth $676K as of Q2 2026.
  • Cliff Asness bought 3,991 Beam Therapeutics shares in Q2 2026, an estimated $120K.
  • Beam Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3233 holding.
  • Cliff Asness first reported a position in Beam Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Cliff Asness's Beam Therapeutics position peaked at $2.38M in Q2 2021.
  • 275 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.